Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...
Sarepta has stopped developing SRP-5051, its exon 51-skipping therapy for Duchenne MD, due to long-term safety concerns and ...
Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...
FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...
Hosted on MSN15d
The role of molecular residual disease in operable non-small cell lung cancer with gene fusionsThe study included 49 NSCLC patients who underwent surgery and had next-generation sequencing (NGS)-confirmed oncogenic fusions, MET exon 14 skipping, or de novo MET amplification. After excluding ...
While the firm agrees with the trial design changes, it continues to hold a conservative view on the program and lowers its target for the delayed timelines as it looks for clarity on the company’s ...
News Medical on MSN16d
Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplificationIn operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback